Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 447 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gliosarcoma Clear all
Completed Phase 1Phase 2 Interventional

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

NCT00107237
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
AEE788, everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Carmustine in Treating Patients With Recurrent Malignant Glioma

NCT00004028
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, conventional surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00165477
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Malignant Gliomas
Interventions
lenalidomide, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 21, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

NCT01095094
View directory record Official record
Conditions
Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma
Interventions
ritonavir, lopinavir
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

NCT00005951
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 21, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

NCT00671801
View directory record Official record
Conditions
Malignant Gliomas
Interventions
Irinotecan, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

NCT00085566
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 21, 2026, 6:41 PM EDT
Terminated Not applicable Interventional

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
View directory record Official record
Conditions
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
Procedure · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 21, 2026, 6:41 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NCT05095376
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
418
States / cities
Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma

NCT07859059
View directory record Official record
Conditions
High Grade Glioma, Glioblastoma, Gliosarcoma
Interventions
Dexbrompheniramine, Temozolomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 6:41 PM EDT
Completed No phase listed Observational

Study of Blood and Cheek Cell Samples From Patients With Glioma

NCT01009307
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polymorphism analysis, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
1,709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00553150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
everolimus, temozolomide, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
178
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 21, 2026, 6:41 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma

NCT02062827
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
Interventions
M032 (NSC 733972)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 6:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00014105
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, temozolomide
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

NCT00014573
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

NCT02330562
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma
Interventions
MRZ, BEV
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Orange, California • Santa Monica, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

NCT00612989
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar and O6-Benzylguanine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

NCT00085540
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
depsipeptide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00841555
View directory record Official record
Conditions
Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions
temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 21, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

NCT00110032
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma
Interventions
EF5, conventional surgery, positron emission tomography, fluorine F 18 EF5, pharmacological study
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT00823797
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Bendamustine Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

GW572016 to Treat Recurrent Malignant Brain Tumors

NCT00107003
View directory record Official record
Conditions
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
Interventions
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 21, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 21, 2026, 6:41 PM EDT